ArticleAnnals of medicine and surgery (2012)2025
Clinical characteristics and predictors of survival in 284 patients with recurrent epithelial ovarian cancer: a large-scale retrospective analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pattern of ovarian cancer recurrence and survival: final analysis of an extended cohort of 591 patients.Wiener medizinische Wochenschrift (1946) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to analyze clinical characteristics, recurrence patterns, and survival predictors in patients with recurrent epithelial ovarian cancer. Methods: We conducted a retrospective analysis of 284 patients with recurrent epithelial ovarian cancer treated at our institution between 2012 and 2022. Clinical data, recurrence patterns, treatment modalities, and survival outcomes were evaluated. Kaplan-Meier analysis and Cox proportional hazards models were used to assess survival and identify prognostic factors. Results: The mean age at recurrence was 54.47 years. Multiple site recurrence (50.70%) was the most common, followed by peritoneal (21.47%) and distant metastases (15.84%). Median progression-free survival (PFS) and overall survival (OS) were 5.00 and 23.00 months, respectively. Retroperitoneal recurrence was associated with better survival compared to distant recurrence (median OS 29.00 vs 16.00 months, Conclusion: Recurrence patterns and timing significantly impact survival in recurrent ovarian cancer. Complete cytoreduction, tumor grade, and initial stage are crucial prognostic factors. These findings emphasize the need for personalized treatment strategies and continued research into novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.